Rheumatoid Arthritis
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias. At EULAR 2023 in Milan, the perfect platform was provided for an airing of grievances, in a debate entitled ‘Clinically suspect arthralgias: fact or myth’.
Dr. John Cush RheumNow
2 years 4 months ago
RA and cancer risk in the biologic era
RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era.
https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly
Dr. John Cush RheumNow
2 years 4 months ago
AI in RA: the story grows along the patient pathway
The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA.
https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM
Dr. Antoni Chan synovialjoints
2 years 4 months ago
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan synovialjoints
2 years 4 months ago
The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2
Dr. John Cush RheumNow
2 years 4 months ago
Better at Predicting RA from MRI: Humans or Computers?
https://t.co/xRVatfiRKS https://t.co/Gwypq8lcdl
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Bella Mehta bella_mehta
2 years 4 months ago
JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
Bella Mehta bella_mehta
2 years 4 months ago
Abstracts talking about #RA and JAKs and Biologic comparisons
Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below
@RheumNow https://t.co/jl5S4fLq19
Bella Mehta bella_mehta
2 years 4 months ago
Abatacept in pts at risk of #RA data from clinical trial.
213 pts, 31 centers.
Pts with multiple autoantibodies improved the most with abatacept.
@rheumnow #EULAR2023 https://t.co/c82jx0cAEq
Poster Hall